Klaus Binder

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada.

Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany.

NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada.